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Transapical Aortic Implantation of Autologous
Marrow Stromal Cell-Based Tissue-Engineered
Heart Valves
First Experiences in the Systemic Circulation
Maximilian Y. Emmert, MD,*‡§ Benedikt Weber, MD,*‡§ Luc Behr, VDM, PHD,
homas Frauenfelder, MD,† Chad E. Brokopp, MSC,*§ Jürg Grünenfelder, MD,‡
Volkmar Falk, MD,‡ Simon P. Hoerstrup, MD, PHD*‡§
Zurich, Switzerland; and Paris, FranceWithin 1 procedure, tissue-engineered, living heart
valves (TEHVs), fabricated from biodegradable
scaffolds seeded with autologous bone marrow–
derived mononuclear cells (Fig. 1A), were inte-
grated into self-expanding nitinol stents (20 mm
30 mm) and transapically delivered into the de-
scending aorta (n  2) (distal to the brachioce-
phalic trunk) and the brachiocephalic trunk (n 1) of
sheep (Fig. 1A). Native valve incompetence was
created by applying the Hufnagel procedure (1)
before implantation (Fig. 1A). After successful
deployment (Figs. 1B and 1C), valve function and
optimal positioning were confirmed using fluoros-
copy (Fig. 1B, Online Video 1), computed tomog-
raphy (CT) (Figs. 1D and 1E, Online Video 2),
and echocardiography (Figs. 1F to 1M, Online
Videos 3A, 3B, and 3C). The crimping time of the
TEHVs was 15  2 min. The overall duration of
the procedure, from the preparation of cells to the
successful delivery, was 2 h. Post-mortem analysis
displayed fully intact TEHVs and, in particular,
well-defined leaflets showing coaptation. There
were no signs of leaflet rupture, microstructure
damage, or thrombus formation detectable.
So far, successful TEHV implantations have
only been reported for low-pressure systems such
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January 25, 2011, accepted February 4, 2011.as in the pulmonary position (2), and clinical trials
have been initiated. This is the first report dem-
onstrating the feasibility of the minimally invasive,
catheter-assisted implantation of TEHV into the
systemic circulation with adequate valvular func-
tionality in an acute study based on an easily
accessible, clinically relevant cell source (3) and
minimally invasive techniques for both cell harvest
and delivery (2) within 1 procedure. Such autolo-
gous and living heart valves may hold potential to
overcome the limitations of the currently used bio-
prosthetic valves inherently prone to calcification and
progressive dysfunctional degeneration. This may
broaden the future clinical application of transcathe-
ter valves beyond elderly high-risk patients.
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APPENDIX
For supplementary videos, please see the online version of this
article.
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(A) Tissue-engineered heart valves (TEHVs) (inset) were transapically delivered into the descending aorta (distal to the brachiocephalic trunk) and into the bra-
chiocephalic trunk of adult sheep after creating native valve insufﬁciency by applying the Hufnagel procedure. (B) Contrast angiography displayed optimal posi-
tioning and normal function of the TEHV. (C) Post-mortem analysis conﬁrmed positioning in the descending aorta distal to the brachiocephalic trunk. (D and E)
Three-dimensional (3D) computed tomography reconstruction of the adult sheep heart (D and E showing anterior view, inset showing posterior view) with the
self-expanding nitinol stent positioned in the descending aorta (‡) distal to the brachiocephalic trunk (*). (F to M) Transesophageal echocardiography (TEE) in
the 2-dimensional (2D); (G and H), 2D color (I), and 3D (J to M) modes displayed the TEHV in the descending aorta (‡) above the native valve (*). In particular,
the TEE analysis showed well-deﬁned leaﬂets showing sufﬁcient coaptation. There were no signs of pressure damage, leaﬂet rupture, or thrombus formation
detectable. Also See Online Videos 1, 2, 3A, 3B, and 3C.
